3 completed, 2 withdrawn, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Withdrawn 2, Terminated 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Stage IIIA Rectal Cancer: new trials by email Literature Review of Stage IIIA Rectal Cancer trials Research Report on Stage IIIA Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment Laboratory Biomarker Analysis, Regorafenib - Rectal Adenocarcinoma, Stage IIA Rectal Cancer | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2015-03-01 | 2016-10-12 | |
| Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer bevacizumab, oxaliplatin, leucovorin calcium - Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum | Phase 2 | Terminated | University of Southern California | 17 | 2013-08-02 | 2026-07-01 |
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2013-03-01 | 2019-09-20 |
| Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma erlotinib hydrochloride, placebo, laboratory biomarker analysis - Adenomatous Polyp, Recurrent Colon Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2008-07-01 | 2015-01-06 |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2005-01-01 | 2015-03-02 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2016-05-20 |
Rectal Neoplasms (6) · Colonic Neoplasms (4) · Adenomatous Polyps (1) · Pancreatic Neoplasms (1)
Colorectal Neoplasms (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Rectal Diseases (6) · Colonic Diseases (4) · Adenoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Neoplasms by Histologic Type (1)
Fluorouracil (2) · Oxaliplatin (2) · Bevacizumab (1) · Erlotinib Hydrochloride (1) · Irinotecan (1) · Leucovorin (1) · MK 2206 (1) · dehydroftorafur (1) · infigratinib (1) · ispinesib (1) · regorafenib (1)
National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (2) · University of Southern California (1)
United States (6)
Afsaneh Barzi (1) · Edmund Kopetz (1) · Patrick Boland (1) · Syma Iqbal, MD (1) · Timothy Morgan (1) · Wen Wee Ma (1)
P30CA016056 (2), N01CM00039 (1), N01CN35160 (1), P30CA014089 (1), P30CA016672 (1)